Study will Examine the Possible Benefits of MytesiŽ on Gut Health, Including Bloating and Abdominal Discomfort, in People Living with HIV SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (`Jaguar` or the `Company`), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has entered into a Master Services Agreement (`the Agreement`) with Integrium, LLC, a clinical research organization that designs, conducts, and analyzes clinical trials. Under the terms of the Agreement and the associated service order, Intergrium will provide clinical...
|